EUVIMEDEUVIMED entdecken
Crossref

Process Development of ABBV-576, a C2 Corrector for the Treatment of Cystic Fibrosis

Nicholas J. Hafeman, Stephen P. Lathrop, Aleksandra Holownia, Kartik Kamat, Louis R. Redfern, Geoff G. Z. Zhang, Nick Rosano, Jeffrey M. Kallemeyn, Kenneth M. Engstrom, John R. Bellettini, John Hartung

Organic Process Research & Development · 30.10.2026

DOI: 10.1021/acs.oprd.6c00264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Organic Process Research & Development, online erschienen am 30.10.2026. Verfasst von Nicholas J. Hafeman und 10 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben. Gefördert von: AbbVie.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development and execution of a second-generation process for the manufacture of ABBV-576, a CFTR C2 corrector for the treatment of cystic fibrosis, are described. Strategic considerations are outlined that address challenges encountered during the manufacture of the phase I-enabling delivery of ABBV-576. The new route features a highly branched-selective Mizoroki–Heck coupling, a Sharpless asymmetric dihydroxylation/cyclization sequence, an alcohol-to-carboxylic acid oxidation on a challenging substrate prone to oxidative decomposition, and an amide coupling to forge the active pharmaceutical ingredient (API). An improved API crystallization addresses issues with solvent removal observed in the original process, and crystallization development work provided insights into a stereoisomeric impurity that was difficult to purge in the penultimate intermediate and API isolations. This paper details the development work performed to establish the second-generation route as well as its execution on a 3 kg scale.

Förderung

  • AbbVie

Zitieren

APA

Hafeman, N. J., Lathrop, S. P., Holownia, A., Kamat, K., Redfern, L. R., Zhang, G. G. Z., Rosano, N., Kallemeyn, J. M., Engstrom, K. M., Bellettini, J. R., & Hartung, J. (2026). Process Development of ABBV-576, a C2 Corrector for the Treatment of Cystic Fibrosis. Organic Process Research & Development. https://doi.org/10.1021/acs.oprd.6c00264

Vancouver

Hafeman NJ, Lathrop SP, Holownia A, Kamat K, Redfern LR, Zhang GGZ, et al. Process Development of ABBV-576, a C2 Corrector for the Treatment of Cystic Fibrosis. Organic Process Research & Development. 2026. doi:10.1021/acs.oprd.6c00264

BibTeX
@article{Hafeman2026,
  author = {Hafeman, Nicholas J. and Lathrop, Stephen P. and Holownia, Aleksandra and Kamat, Kartik and Redfern, Louis R. and Zhang, Geoff G. Z. and Rosano, Nick and Kallemeyn, Jeffrey M. and Engstrom, Kenneth M. and Bellettini, John R. and Hartung, John},
  title = {Process Development of ABBV-576, a C2 Corrector for the Treatment of Cystic Fibrosis},
  journal = {Organic Process Research & Development},
  year = {2026},
  doi = {10.1021/acs.oprd.6c00264}
}
Kostenlos starten →